^
Association details:
| Biomarker: | KRAS mutation + ATM mutation |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report
Published date:
07/16/2021
Excerpt:
...we report a K-RAS/ATM mutation rectal cancer patient with multiple liver metastases (CRS = 5 points) who had a pCR of hepatic metastasis and cCR of primary rectal cancer after XELOXIRI plus bevacizumab. The patient was disease-free at 37 months after treatment at the last follow-up in May 2021.
Secondary therapy:
XELOXIRI
DOI:
10.2147/OTT.S320477
